9 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 14 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 9, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 4, Recruiting 2 |
Follow Desmoid Tumors: new trials by email Literature Review of Desmoid Tumors trials Research Report on Desmoid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP). ST316 IV - Familial Adenomatous Polyposis (FAP) | Phase 1 | Not yet recruiting | Sapience Therapeutics | 40 | 2027-01-04 | 2026-08-12 |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors FOG-001, mFOLFOX-6, Nivolumab - Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Parabilis Medicines, Inc. | 619 | 2023-05-23 | 2026-10-07 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor vactosertib/imatinib combination - Desmoid Tumor | Phase 1 / Phase 2 | Completed | Hyo Song Kim | 24 | 2019-04-15 | 2024-05-13 |
| A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) E7386 - Solid Neoplasms, Colorectal Neoplasms | Phase 1 | Active not recruiting | Eisai Co., Ltd. | 70 | 2019-03-05 | 2026-02-27 |
| Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 Tegavivint - Desmoid Tumor | Phase 1 | Completed | Iterion Therapeutics | 24 | 2018-07-15 | 2023-03-01 |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers Nab-Rapamycin, Nivolumab - Ewing Sarcoma, PEComa | Phase 1 / Phase 2 | Completed | Sarcoma Oncology Research Center, LLC | 34 | 2017-08-24 | 2025-02-17 |
| HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors Doxorubicin HCl liposomal injection, Philips Sonalleve MR-HIFU Hyperthermia - Rhabdomyosarcoma, Neuroblastoma | Phase 1 | Withdrawn | Theodore Laetsch | 2016-12-01 | 2019-03-19 | |
| MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors Magnetic Resonance High Intensity Focused Ultrasound - Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors | Phase 1 | Completed | AeRang Kim | 7 | 2014-04-01 | 2025-01-01 |
| A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Sirolimus - Desmoid Tumor | Phase 1 / Phase 2 | Completed | MaineHealth | 9 | 2014-02-01 | 2023-06-26 |
| Endoxifen in Adults With Hormone Receptor Positive Solid Tumors Z-Endoxifen - Hormone Receptor-Positive Breast, Gynecologic | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2011-03-01 | 2025-12-23 |
| Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate Imatinib mesylate, Cyclophosphamide (Dosing level 1 ), Imatinib mesylate, Cyclophosphamide (Dosing level 2), Imatinib mesylate, Cyclophosphamide (Dosing level 3) - Cancer | Phase 1 | Completed | Centre Oscar Lambret | 26 | 2009-02-09 | 2026-09-17 |
| Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis imatinib mesylate - Desmoid Tumor | Phase 1 / Phase 2 | Completed | UNICANCER | 40 | 2004-09-01 | 2016-08-30 |
| MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma entinostat - Cancer | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 75 | 2001-03-01 | 2012-03-15 |
Carcinoma, Hepatocellular (6) · Colorectal Neoplasms (4) · Endometrial Neoplasms (4) · Osteosarcoma (4) · Sarcoma, Ewing (4) · Melanoma (3) · Neoplasms (3) · Neuroblastoma (3) · Sarcoma (3) · Wilms Tumor (3) · Adenomatous Polyposis Coli (2) · Adrenocortical Carcinoma (2) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2)
Fibroma (14) · Neoplasms by Histologic Type (14) · Neoplasms, Connective Tissue (14) · Neoplasms, Connective and Soft Tissue (14) · Neoplasms, Fibrous Tissue (14) · Neoplasms (11) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Digestive System Diseases (8) · Adenocarcinoma (7) · Carcinoma (7) · Digestive System Neoplasms (7) · Gastrointestinal Diseases (7) · Gastrointestinal Neoplasms (7) · Neoplasms, Nerve Tissue (7)
Imatinib Mesylate (2) · Nivolumab (2) · 4-hydroxy-N-desmethyltamoxifen (1) · Absorptiometry, Photon (1) · Bevacizumab (1) · Blood Specimen Collection (1) · Bone Density (1) · Cyclophosphamide (1) · E-7386 (1) · Fluorouracil (1) · Leucovorin (1) · Oxaliplatin (1) · Phantoms, Imaging (1) · Sirolimus (1) · Specimen Handling (1)
AeRang Kim (1) · Centre Oscar Lambret (1) · Children's Oncology Group (1) · Eisai Co., Ltd. (1) · Hyo Song Kim (1) · Iterion Therapeutics (1) · MaineHealth (1) · National Cancer Institute (NCI) (1) · National Institutes of Health Clinical Center (CC) (1) · Parabilis Medicines, Inc. (1) · Sapience Therapeutics (1) · Sarcoma Oncology Research Center, LLC (1) · Theodore Laetsch (1) · UNICANCER (1)
United States (9) · France (2) · Australia (1) · Canada (1) · Japan (1) · South Korea (1)
Aaron R Weiss, DO (1) · AeRang Kim, MD, PhD (1) · Alice P Chen, M.D. (1) · Benjamin Oshrine (1) · Erlinda M Gordon, MD (1) · Jean-Yves Blay, MD, PhD (1) · Sarah B Whittle (1) · Shivaani Kummar, MD (1)
PMID 31401903, PMID 20622000, PMID 24089446, PMID 39956770
2008 (1), UM1CA228823 (1)